ES2544153A1 - Uso de un hidrolizado de caseína como agente antiviral - Google Patents

Uso de un hidrolizado de caseína como agente antiviral Download PDF

Info

Publication number
ES2544153A1
ES2544153A1 ES201430248A ES201430248A ES2544153A1 ES 2544153 A1 ES2544153 A1 ES 2544153A1 ES 201430248 A ES201430248 A ES 201430248A ES 201430248 A ES201430248 A ES 201430248A ES 2544153 A1 ES2544153 A1 ES 2544153A1
Authority
ES
Spain
Prior art keywords
casein hydrolyzate
antiviral agent
translation
machine
legally binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201430248A
Other languages
English (en)
Other versions
ES2544153B1 (es
Inventor
Pere ADELL WINKLER
Guillermo LÓPEZ ZARCO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTD Labs SL
Original Assignee
NTD Labs SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201430248A priority Critical patent/ES2544153B1/es
Application filed by NTD Labs SL filed Critical NTD Labs SL
Priority to DK15710916.6T priority patent/DK3110430T3/da
Priority to US15/121,080 priority patent/US10772927B2/en
Priority to PT157109166T priority patent/PT3110430T/pt
Priority to EP15710916.6A priority patent/EP3110430B1/en
Priority to PCT/IB2015/051157 priority patent/WO2015125067A1/en
Priority to ES15710916T priority patent/ES2746523T3/es
Publication of ES2544153A1 publication Critical patent/ES2544153A1/es
Application granted granted Critical
Publication of ES2544153B1 publication Critical patent/ES2544153B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de un hidrolizado de caseína como agente antiviral. La presente invención se refiere al uso de un hidrolizado de caseína como agente antiviral para el tratamiento de infecciones por virus oportunistas, especialmente por herpesvirus y el virus del papiloma humano. Dicho hidrolizado de caseína tiene aplicación tanto en el tratamiento terapéutico de los síntomas establecidos como en la prevención de la infección o de la reactivación de una infección latente por un virus oportunista. El hidrolizado de caseína de la presente invención es efectivo para la prevención de las infecciones por virus oportunistas en individuos con el sistema inmunitario debilitado.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
    imagen2
ES201430248A 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral Expired - Fee Related ES2544153B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES201430248A ES2544153B1 (es) 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral
US15/121,080 US10772927B2 (en) 2014-02-24 2015-02-17 Use of a casein hydrolysate as an antiviral agent
PT157109166T PT3110430T (pt) 2014-02-24 2015-02-17 Utilização de um hidrolisado de caseína como um agente antiviral
EP15710916.6A EP3110430B1 (en) 2014-02-24 2015-02-17 Use of a casein hydrolysate as an antiviral agent
DK15710916.6T DK3110430T3 (da) 2014-02-24 2015-02-17 Brug af kasein hydrolysat som en antiviral agent
PCT/IB2015/051157 WO2015125067A1 (en) 2014-02-24 2015-02-17 Use of a casein hydrolysate as an antiviral agent
ES15710916T ES2746523T3 (es) 2014-02-24 2015-02-17 Uso de un hidrolizado de caseína como agente antivírico

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430248A ES2544153B1 (es) 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral

Publications (2)

Publication Number Publication Date
ES2544153A1 true ES2544153A1 (es) 2015-08-27
ES2544153B1 ES2544153B1 (es) 2016-06-06

Family

ID=52693000

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430248A Expired - Fee Related ES2544153B1 (es) 2014-02-24 2014-02-24 Uso de un hidrolizado de caseína como agente antiviral
ES15710916T Active ES2746523T3 (es) 2014-02-24 2015-02-17 Uso de un hidrolizado de caseína como agente antivírico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15710916T Active ES2746523T3 (es) 2014-02-24 2015-02-17 Uso de un hidrolizado de caseína como agente antivírico

Country Status (6)

Country Link
US (1) US10772927B2 (es)
EP (1) EP3110430B1 (es)
DK (1) DK3110430T3 (es)
ES (2) ES2544153B1 (es)
PT (1) PT3110430T (es)
WO (1) WO2015125067A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073824B1 (ko) * 2018-04-11 2020-02-05 강원대학교산학협력단 간 보호용 건강기능식품 및 이의 제조 방법
FR3083981B1 (fr) * 2018-07-20 2021-01-15 Semiocare Sas Compositions a usage cosmetique et dermatologique
US20210106525A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
ES2940736B2 (es) * 2021-11-09 2023-09-19 Ntd Labs S L U Uso combinado de imiquimod y de un hidrolizado de caseina para el tratamiento de condilomas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045524A2 (en) * 2000-12-07 2002-06-13 Dsm Ip Assets B.V. Prolyl endoprotease from aspergillus niger
US20110082281A1 (en) * 2003-08-01 2011-04-07 Calpis Co., Ltd. Casein hydrolyzate, process for producing the same and use thereof
WO2011138489A1 (es) * 2010-05-06 2011-11-10 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de caseínas como antivirales

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922453A1 (de) 1989-07-07 1991-01-17 Gauri Kailash Kumar Pharmakologisch wirksame produkte aus molkeproteinhydrolysaten und verfahren zu deren gewinnung
CA2107460A1 (en) 1991-04-01 1992-10-02 Vladimir K. Khavinson Pharmaceutical dipeptide compositions and methods of use thereof
KR20010006378A (ko) * 1997-04-15 2001-01-26 어드밴스드 바이럴 리서치 코포레이션 유두종 바이러스 감염의 치료법
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
TWI317636B (en) * 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
US20050148504A1 (en) * 2002-11-29 2005-07-07 Nobuhiko Katunuma Cysteine protease inhibitor
CN104703601A (zh) 2012-07-03 2015-06-10 格雷斯兰生物科技股份有限公司 用于治疗和抑制病毒感染的组合物和方法
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045524A2 (en) * 2000-12-07 2002-06-13 Dsm Ip Assets B.V. Prolyl endoprotease from aspergillus niger
US20110082281A1 (en) * 2003-08-01 2011-04-07 Calpis Co., Ltd. Casein hydrolyzate, process for producing the same and use thereof
WO2011138489A1 (es) * 2010-05-06 2011-11-10 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de caseínas como antivirales

Also Published As

Publication number Publication date
ES2746523T3 (es) 2020-03-06
EP3110430A1 (en) 2017-01-04
US10772927B2 (en) 2020-09-15
US20160361374A1 (en) 2016-12-15
ES2544153B1 (es) 2016-06-06
EP3110430B1 (en) 2019-06-26
WO2015125067A1 (en) 2015-08-27
DK3110430T3 (da) 2019-09-23
PT3110430T (pt) 2019-10-15

Similar Documents

Publication Publication Date Title
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
BR112017014209A2 (pt) design de aparelhos dentários auxiliado por sistema de computador
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
PH12017500207B1 (en) Indoles for use in influenza virus infection
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
MY196095A (en) Antibody That Binds to Envelope Glycoprotein of Severe Fever With Thrombocytopenia Syndrome Virus and use for Same
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
BR112015029264A2 (pt) localização de dispositivo com o uso de câmera e sinal sem fio
EA202090683A3 (ru) Способы и композиции для лечения рака
NZ773652A (en) Β-d-2’-deoxy-2’-α-fluoro-2’-β-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
TR201911232T4 (tr) Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler.
JP2016524748A5 (es)
ES2544153A1 (es) Uso de un hidrolizado de caseína como agente antiviral
BR112015012778A2 (pt) estrutura de suporte de componente de escapamento
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
BR112018071547A2 (pt) acetil-leucina ou um sal farmaceuticamente aceitável desta
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: NTD LABS, S.L.

Effective date: 20150522

FG2A Definitive protection

Ref document number: 2544153

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160606

FD2A Announcement of lapse in spain

Effective date: 20211004